Geron (FRA:GON) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:GON Geron Corp FRA:GON
39 GF Score
Price €1.21
GF Value €5.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Geron's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:GON vs LBRX, ODTX, OMER: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Geron's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geron Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Geron's Margin of Safety % (DCF Earnings Based) falls into.


FRA:GON
39GF Score
Geron Corp FRA:GON
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Geron (FRA:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.21 is trading 78.2% below its estimated GF Value™ of €5.55. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for FRA:GON:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €5.55 vs. price of €1.21 (78.2% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score

Get the complete analysis for FRA:GON

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price
€5.55
GF Value